Suppr超能文献

炎症性肠病自然史中的关键步骤。

Crucial steps in the natural history of inflammatory bowel disease.

机构信息

Gastroenterology Unit, Department of Internal Medicine and Public Health, University of L'Aquila, L'Aquila, Italy.

出版信息

World J Gastroenterol. 2012 Aug 7;18(29):3790-9. doi: 10.3748/wjg.v18.i29.3790.

Abstract

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic, progressive and disabling disorders. Over the last few decades, new therapeutic approaches have been introduced which have led not only to a reduction in the mortality rate but also offered the possibility of a favorable modification in the natural history of IBD. The identification of clinical, genetic and serological prognostic factors has permitted a better stratification of the disease, thus allowing the opportunity to indicate the most appropriate therapy. Early treatment with immunosuppressive drugs and biologics has offered the opportunity to change, at least in the short term, the course of the disease by reducing, in a subset of patients with IBD, hospitalization and the need for surgery. In this review, the crucial steps in the natural history of both UC and CD will be discussed, as well as the factors that may change their clinical course. The methodological requirements for high quality studies on the course and prognosis of IBD, the true impact of environmental and dietary factors on the clinical course of IBD, the clinical, serological and genetic predictors of the IBD course (in particular, which of these are relevant and appropriate for use in clinical practice), the impact of the various forms of medical treatment on the IBD complication rate, the role of surgery for IBD in the biologic era, the true magnitude of risk of colorectal cancer associated with IBD, as well as the mortality rate related to IBD will be stressed; all topics that are extensively discussed in separate reviews included in this issue of World Journal of Gastroenterology.

摘要

炎症性肠病(IBD),包括溃疡性结肠炎(UC)和克罗恩病(CD),是慢性、进行性和致残性疾病。在过去的几十年中,已经引入了新的治疗方法,不仅降低了死亡率,而且还提供了改善 IBD 自然史的可能性。临床、遗传和血清学预后因素的确定允许对疾病进行更好的分层,从而有机会指出最合适的治疗方法。早期使用免疫抑制剂和生物制剂治疗为至少在短期内改变疾病进程提供了机会,通过减少一部分 IBD 患者的住院和手术需求。在这篇综述中,将讨论 UC 和 CD 的自然史中的关键步骤,以及可能改变其临床病程的因素。将强调高质量研究在 IBD 病程和预后方面的方法学要求、环境和饮食因素对 IBD 临床病程的真正影响、IBD 病程的临床、血清学和遗传预测因素(特别是这些因素中哪些与临床实践相关且适用)、各种形式的医学治疗对 IBD 并发症发生率的影响、生物时代 IBD 手术的作用、IBD 相关结直肠癌的真正风险程度以及与 IBD 相关的死亡率;所有这些主题都在本卷《世界胃肠病学杂志》中的单独综述中进行了广泛讨论。

相似文献

1
Crucial steps in the natural history of inflammatory bowel disease.炎症性肠病自然史中的关键步骤。
World J Gastroenterol. 2012 Aug 7;18(29):3790-9. doi: 10.3748/wjg.v18.i29.3790.
5
The epidemiology of inflammatory bowel disease.炎症性肠病的流行病学
Scand J Gastroenterol. 2015 Aug;50(8):942-51. doi: 10.3109/00365521.2015.1014407. Epub 2015 Feb 17.
8
Current therapeutic approaches in inflammatory bowel disease.炎症性肠病的当前治疗方法。
Curr Pharm Des. 2010;16(33):3668-83. doi: 10.2174/138161210794079155.

引用本文的文献

3
Role of pH-sensing receptors in colitis.酸感应受体在结肠炎中的作用。
Pflugers Arch. 2024 Apr;476(4):611-622. doi: 10.1007/s00424-024-02943-y. Epub 2024 Mar 22.
4
Pterostilbene: a potential therapeutic agent for fibrotic diseases.紫檀芪:一种潜在的抗纤维化疾病治疗剂。
Inflammopharmacology. 2024 Apr;32(2):975-989. doi: 10.1007/s10787-024-01440-z. Epub 2024 Mar 1.
5
The inflammatory bowel disease care manager: Italian state of the art.炎症性肠病护理经理:意大利的最新情况
Ann Gastroenterol. 2024 Jan-Feb;37(1):37-45. doi: 10.20524/aog.2023.0852. Epub 2023 Dec 23.

本文引用的文献

10
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.艰难梭菌感染与炎症性肠病:综述
Gastroenterol Res Pract. 2011;2011:136064. doi: 10.1155/2011/136064. Epub 2011 Sep 12.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验